Stockscreener 앱 받기
11.26
2.23%
-0.295
전일 마감가:
$11.55
열려 있는:
$11.5
하루 거래량:
37,084
Relative Volume:
0.03
시가총액:
$861.22M
수익:
$31,000
순이익/손실:
$-54.42M
주가수익비율:
-11.51
EPS:
-0.9778
순현금흐름:
$-48.99M
1주 성능:
+4.08%
1개월 성능:
-16.97%
6개월 성능:
+126.31%
1년 성능:
+114.28%
1일 변동 폭
$11.24
$11.55
1주일 범위
$10.85
$12.01
52주 변동 폭
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
11.26 | 883.79M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
521.60 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.31 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
193.83 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.69 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.53 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics upgraded to Strong Buy afte... - Pluang
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL) - Seeking Alpha
H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics stock jumps on BofA upgrade to buy - Investing.com
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics stock jumps on BofA upgrade to buy By Investing.com - Investing.com South Africa
BofA upgrades Candel Therapeutics stock rating on prostate cancer progress - Investing.com
Why is Candel Therapeutics stock surging today? By Investing.com - Investing.com Canada
BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18 - marketscreener.com
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics Inc (NASDAQ:CADL) Share Price | RNS News, Quotes, & Charts | CADL | - Proactive financial news
Candel Therapeutics at H.C. Wainwright conference: prostate cancer push By Investing.com - Investing.com India
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Slides As Candel Therapeutics Posts Wider Q2 Loss - StocksToTrade
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock - Investing.com
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - manilatimes.net
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
A drug-development expert with 30 years’ experience joins Candel’s board - Stock Titan
CADL Q2 2026 Earnings: EPS of -$0.52 Misses Consensus by 115.41% as Shares Decline 3.41%Quarterly Financial Update - careplusvn.com
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 - investing.com
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - manilatimes.net
Candel (CADL) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Stock Move: The Share Price Adds 6.32% in the Latest ReadingHealthcare Earnings Report - careplusvn.com
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Candel Therapeutics Inc 주식 (CADL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer |
Sep 10 '26 |
Sale |
11.50 |
220,866 |
2,539,893 |
172,700 |
| Tak Paul Peter | Chief Executive Officer |
Sep 11 '26 |
Sale |
10.46 |
59,379 |
620,891 |
113,321 |
0.76%
0.26%
자본화:
|
볼륨(24시간):